Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-02-29

Clinical Trial Update: An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia [Phase 2]

View source ↗

Summary

Phase 2 trial assessing the efficacy of LY2624803 for chronic insomnia (primary and secondary insomnia) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LY2624803 (LY2624803)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Primary Insomnia, Secondary Insomnia | Phase 2 | Status: COMPLETED | Results posted: 2012-02-29